187 related articles for article (PubMed ID: 18066142)
1. Postmarket surveillance of natural health products in Canada: clinical and federal regulatory perspectives.
Murty M
Can J Physiol Pharmacol; 2007 Sep; 85(9):952-5. PubMed ID: 18066142
[TBL] [Abstract][Full Text] [Related]
2. Governance of natural health products regulation: an iterative process.
Walji R; Wiktorowicz M
Health Policy; 2013 Jun; 111(1):86-94. PubMed ID: 23523344
[TBL] [Abstract][Full Text] [Related]
3. Model competencies in regulatory therapeutic product assessment: Health Canada's good review guiding principles as a reviewing community's code of intellectual conduct.
Lim RR
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):933-41. PubMed ID: 17290483
[TBL] [Abstract][Full Text] [Related]
4. Regulation of natural health products in Canada.
Smith A; Jogalekar S; Gibson A
J Ethnopharmacol; 2014 Dec; 158 Pt B():507-10. PubMed ID: 24969823
[TBL] [Abstract][Full Text] [Related]
5. The Canadian Natural Health Products (NHP) regulations: industry perceptions and compliance factors.
Laeeque H; Boon H; Kachan N; Cohen JC; D'Cruz J
BMC Health Serv Res; 2006 May; 6():63. PubMed ID: 16734916
[TBL] [Abstract][Full Text] [Related]
6. Challenges in natural health product research: The importance of standardization.
Shan JJ; Rodgers K; Lai CT; Sutherland SK
Proc West Pharmacol Soc; 2007; 50():24-30. PubMed ID: 18605225
[TBL] [Abstract][Full Text] [Related]
7. The future of population-based postmarket drug risk assessment: a regulator's perspective.
Hammad TA; Neyarapally GA; Iyasu S; Staffa JA; Dal Pan G
Clin Pharmacol Ther; 2013 Sep; 94(3):349-58. PubMed ID: 23739537
[TBL] [Abstract][Full Text] [Related]
8. Natural health product use in Canada: analysis of the National Population Health Survey.
Singh SR; Levine MA
Can J Clin Pharmacol; 2006; 13(2):e240-50. PubMed ID: 16921199
[TBL] [Abstract][Full Text] [Related]
9. Community identification of natural health product-drug interactions.
Charrois TL; Hill RL; Vu D; Foster BC; Boon HS; Cramer K; Vohra S
Ann Pharmacother; 2007 Jul; 41(7):1124-9. PubMed ID: 17578882
[TBL] [Abstract][Full Text] [Related]
10. Self-reported use of natural health products: a cross-sectional telephone survey in older Ontarians.
Levine MA; Xu S; Gaebel K; Brazier N; Bédard M; Brazil K; Lohfeld L; MacLeod SM
Am J Geriatr Pharmacother; 2009 Dec; 7(6):383-92. PubMed ID: 20129259
[TBL] [Abstract][Full Text] [Related]
11. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
Roller ST; Pippins RR; Ngai JW
Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
[TBL] [Abstract][Full Text] [Related]
12. Legislative initiatives in Europe, Canada and the US for market authorization of follow-on biologics.
Looper YJ
Curr Opin Drug Discov Devel; 2010 Mar; 13(2):247-56. PubMed ID: 20205058
[TBL] [Abstract][Full Text] [Related]
13. A descriptive study evaluating Health Canada's risk communications.
Bateman J; Charrois TL; Gardiner P; Vohra S
Pharmacoepidemiol Drug Saf; 2011 Oct; 20(10):1104-9. PubMed ID: 21692140
[TBL] [Abstract][Full Text] [Related]
14. Safety and nutritional assessment of GM plants and derived food and feed: the role of animal feeding trials.
EFSA GMO Panel Working Group on Animal Feeding Trials
Food Chem Toxicol; 2008 Mar; 46 Suppl 1():S2-70. PubMed ID: 18328408
[TBL] [Abstract][Full Text] [Related]
15. The US drug safety system: role of the pharmaceutical industry.
Gibson BR; Suh R; Tilson H
Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
[TBL] [Abstract][Full Text] [Related]
16. Moral regulation and the presumption of guilt in Health Canada's medical cannabis policy and practice.
Lucas P
Int J Drug Policy; 2009 Jul; 20(4):296-303. PubMed ID: 19124233
[TBL] [Abstract][Full Text] [Related]
17. Changes in European legislation make it timely to introduce a transparent market surveillance system for cosmetics.
Lodén M; Ungerth L; Serup J
Acta Derm Venereol; 2007; 87(6):485-92. PubMed ID: 17989885
[TBL] [Abstract][Full Text] [Related]
18. FDA attempting to overcome major roadblocks in monitoring drug safety.
Zielinski SL
J Natl Cancer Inst; 2005 Jun; 97(12):872-3. PubMed ID: 15956645
[No Abstract] [Full Text] [Related]
19. Biosimilars approval process.
Zuñiga L; Calvo B
Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of natural health product use in healthy postmenopausal women.
Daoust JL; Mercer LC; Duncan AM
Menopause; 2006; 13(2):241-50. PubMed ID: 16645538
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
